drugset / Trial / NCT05720767
HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study
Non-randomizedParallel-groupOpen-labelOther
Summary
A Phase 1, Open-label, 2-Part, 2-Period Fixed-Sequence Crossover Study to Assess the Effect of Itraconazole, a CYP3A and P-glycoprotein Inhibitor, and the Effect of Rifampin, a CYP Enzyme Inducer, on the Pharmacokinetics of HMPL-523 in Healthy Volunteers
Timeline
- Start
- 2022-11-04
- Primary completion
- 2023-02-05
- Completion
- 2023-02-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Itraconazole | Small molecule | 200 mg | Oral |
| Subject | Rifampin | Small molecule | 600 mg | Oral |
| Subject | Sovleplenib | Small molecule | 400 mg | Oral |
| Subject | Sovleplenib | Small molecule | 700 mg | Oral |